CS Paper Radar

Sliding-scale Insulin Does Not Control Steroid-induced Hyperglycemia in a Non-diabetic Patient, No Matter How You Tune It

Nir Regev, Guy Regev

eess.SY eess.SPq-bio.TO ·submitted 2026-10-06 17:32 UTC · v2
unusual

Abstract

Sliding-scale insulin is the default hospital response to high blood glucose. Its correction factor was designed for patients who make no insulin, yet it is routinely ordered for patients whose pancreas still works, including those on high-dose steroids. We treat the sliding scale as what it is, a proportional controller sampled every four hours, acting on a patient who already contains a working glucose controller of her own. We test it in a non-diabetic adolescent on high-dose corticosteroids and parenteral nutrition, and in 4,995 virtual patients. It fails for three structural reasons, and no choice of correction factor fixes any of them. First, the patient's own loop settles in 11.5 minutes while injected insulin takes 64 minutes to peak, so most of each dose simply replaces insulin she would have secreted; in simulation the ordered scale moved her mean glucose by less than 1.5 mg/dL. Second, one unit lowers glucose twice as much at 110 mg/dL as at 190, so any correction factor strong enough to work when glucose is high overshoots when it is low; in 99.5% of virtual patients no constant factor does both. Third, four-hour sampling is far below the Nyquist rate, so successive readings are uncorrelated and each dose responds to a value that does not persist. Even the argument that correction doses rest the beta cells, taken on its own terms, favors continuous delivery. We propose replacing the scale with a continuous insulin infusion co-delivered with the dextrose and adjusted once a day on mean glucose, the one quantity four-hour monitoring can measure.

Comment
19 pages, 3 figures, 5 tables. Submitted to Communications Medicine

Closest papers

Nearest neighbours by meaning across the whole index.

GlucoPRISM: Protocol-Supervised Pretraining for Cross-Cohort Glucose Transfer

cs.LG ·2026-10-08 ·Adinath Madhavrao Dukre, Abdullah Mohammad, Yifan Lu, Eran Segal, Ahmed Metwally +1 more
similarity 0.50
Abstract

Continuous glucose monitoring (CGM) foundation models encode each day as one vector that mixes who the person is, what happened that day and how the sensor measured it, so measurement differences travel with the representation into new cohorts. We ask whether pretraining can place the measurement component that harms transfer in known coordinates, so that deployment drops them with a fixed projection and no target data. GlucoPRISM supervises a GlucoFM backbone with response contracts, rules for how each part of the representation should change when only the day or only the sensor changes: a 64-dimensional Trait band should change with neither, a 48-dimensional State band only across days, and a 16-dimensional Sensor band should track the device. Synthetic sensor views calibrated on paired Dexcom and Libre recordings, different-day pairs and glucose-summary targets supply this supervision without clinical labels. Across twelve cross-cohort directions, dropping the Sensor band from the same frozen encoder raises mean transfer AUROC from 68.75 to 73.57, against 69.3 for GlucoFM. The gain has two parts. Into CGMacros, the one target cohort recorded with two sensor types, filtering adds 11 to 19 points, and this holds when the generator is recalibrated on half of the participants and scored on the other half. On the other eight directions filtering is neutral and the encoder itself exceeds GlucoFM by 3.5 points. The device remains linearly decodable after filtering, so the filter removes a device-related component that harms transfer rather than all measurement information. The retained bands improve window AUROC on thirteen of fourteen public task--cohort cells (Holm-adjusted p=0.031) and correlation on fourteen of fifteen clinical endpoints in an external cohort of 9,303 participants.

0.16

Sensitivity-driven Personalization of a Glucoregulatory Model for Digital Twin Therapeutics in Type 1 Diabetes

eess.SY ·2026-09-25 ·Clara Escorihuela-Altaba, Vihangkumar V. Naik, Eleonora Manzoni, Jose Garcia-Tirado
similarity 0.47
Abstract

Digital twins are increasingly used in diabetes research, but reproducing individual glucose dynamics requires accurate identification of glucoregulatory model parameters. Traditional sensitivity analysis can identify influential parameters, yet a ranking based on limited conditions may miss parameters that matter during specific disturbances or for particular individuals. We therefore examine both the magnitude and timing of parameter influence across dynamic input-output conditions and assess whether a common ranking holds across participants. We analyze the Hovorka glucoregulatory model using data from 192 participants receiving automated insulin delivery therapy in the Type 1 Diabetes and Exercise Initiative dataset. We extend Sobol sensitivity analysis to time series and rank parameter influence under four conditions: full-day profiles, isolated meal disturbances, insulin bolus injections, and postprandial responses. We combine the condition-specific results into a global ranking and use it to select parameters for participant-specific identification. Compared with population parameters, identification restricted to the sensitivity-derived subset reduces the root mean square error of 60-minute glucose predictions by 60%, to approximately 31 mg/dL. These findings suggest that a global ranking can capture parameter influence across individuals and dynamic conditions. By narrowing the parameters requiring identification, this approach reduces computational cost and could accelerate the development of personalized diabetes digital twins.

0.20

Evaluating Type-1 Diabetes Digital Twins by Decision Quality

cs.LG ·2026-10-22 ·Victor Li, Owen Tucker, Michael S. Hughes, Temiloluwa Prioleau, Shengpu Tang
code/data similarity 0.43
Abstract · 12 pages, 1 figure, 7 tables. Code: https://github.com/Veeeeeee7/T1D-Digital-Twin-Benchmark

A digital twin (DT) for type 1 diabetes (T1D) can predict how an individual's blood glucose will respond to different insulin treatments without actually trying them. For each treatment, downstream statistics of predicted glucose trajectories, such as glycemic risk, can be computed to guide clinical decisions. However, the quality of DTs is usually measured by the accuracy of their predicted glucose trajectories, which may not reflect the quality of the downstream treatment decisions they inform. In this work, we directly evaluate DTs by this decision quality on downstream treatment ranking, i.e., whether a DT predicts glucose trajectories that can be used to rank candidate treatments as the real patient would. We present an evaluation protocol over 30 virtual patients from the FDA-accepted UVA/Padova model, each simulated under 21 different basal-bolus treatments. For each patient, a DT is fitted under one treatment and then produces glucose trajectories for the remaining 20 treatments. Our results show that prediction accuracy and decision quality disagree. A baseline that models the average patient, never seeing the individual's glucose data, has the lowest prediction accuracy of all six methods (RMSE: 63.6 mg/dL) but ranks treatments with the second-highest mean Spearman (0.766), while a black-box neural network that predicts glucose nearly twice as accurately (RMSE: 32.9 mg/dL) ranks them no better than a random ordering of the 20 treatments (0.049 Spearman). Therefore, selecting a DT based on prediction accuracy alone can prefer one that recommends treatments at chance, and decision quality must be evaluated directly rather than assumed to follow from prediction accuracy.

0.34

Safe Data-Driven Insulin Dosage Decision Based on Physiology-Constrained Gaussian Process Learning

eess.SY ·2026-11-19 ·Deheng Cai, Xiang Lu, Wei Liu, Jing Chen, Linong Ji +1 more
similarity 0.43
Abstract

Multiple daily injections (MDI) therapy is widely adopted by insulin-treated subjects with diabetes mellitus. In this work, we study how to ensure that data-driven model learning is aligned with the underlying physiological principles, and introduce a safe data-driven learning and decision framework for the MDI therapy. To provide credible glucose predictions for the decision, a physiology-constrained Gaussian process learning method is developed for glycemic dynamics modeling by encoding the physiological priors as constraints in the model training. Considering the natural day-to-day cycle of insulin decisions, a prediction-based optimization formulation with an objective function that has a penalty term associated with the previous dosage is employed for the insulin therapy, together with the asymmetric penalties on hyper- and hypoglycemia for safety. The effectiveness of the proposed method is verified using the 10-adult cohort from the FDA-accepted UVA/Padova T1DM simulator, and an advisory mode analysis is also conducted based on the clinical data from 40 type 1 diabetes and 55 type 2 diabetes subjects to indicate the safe and physiologically plausible decisions in the real-life applications.

0.27

FairGlucose: A CGM Fairness Benchmark Reveals Subgroup Disparities Hidden in Population-Level Validation

cs.CY cs.AI ·2026-08-18 ·Junjie Luo, Xuzhe Zhi, Rui Han, Abhimanyu Kumbara, Anand K. Iyer +3 more
benchmark similarity 0.40
Abstract

As CGM-based AI tools approach clinical deployment, whether their accuracy is equitable across patient demographics remains insufficiently tested. To enable this evaluation, we constructed FairGlucose, a 300-patient CGM cohort balanced across 12 demographic strata (age x gender x type 1/type 2 diabetes), with 132,480 forecasting samples and 3,945 unique behavioral events (meals, exercise, medication) logged by 81 patients. Benchmarking 33 models across four families on 2-hour glucose forecasting, we find that population-level external validation can conceal substantial subgroup disparities. Aggregate out-of-distribution metrics appear stable (approximately 1.0), yet subgroup-level ratios range from 0.8 to 1.4, with T1D patients showing 6 mg/dL higher prediction error than T2D (p < 0.001). This disparity persists across all 33 models, suggesting a property of the prediction task rather than any single architecture. Further analysis shows that subgroup performance gaps align with the proportion of clinically hard cases, and that input-length sensitivity varies across demographics, motivating personalized configurations. Frontier LLMs underperform specialized neural models by 1-6 mg/dL; behavioral events contribute negligibly (approximately 0.1 mg/dL) even under oracle event access. These findings establish that population-level validation alone is insufficient for equity assessment of digital health AI, motivating subgroup-disaggregated reporting as a default standard.

0.29

DiabAgent: Toward Agentic Physiological Control

cs.AI cs.CL ·2026-11-02 ·Chengxi Li, Shaoxuan Li, Deyao Hong, Qingle Liu, Yi Huang +11 more
benchmarkcode/data similarity 0.38
Abstract

As pretraining scales, medical language models have advanced rapidly in clinical question answering. Their ability to achieve effective physiological control through sustained intervention still lacks systematic quantitative evaluation. Type 1 diabetes provides a concrete setting: impaired insulin secretion creates dependence on exogenous insulin, with dosing continually adjusted using information about meals, exercise, illness, and glucose measurements. We introduce DiabAgent, a research suite for agentic physiological control comprising the Agentic Physiological Control (APC) framework, the DiabetSim simulator, and the SweetBench benchmark. APC controls glucose through medical-device tools, using ongoing observations to infer individual states, accumulate personal experience, and choose treatment actions. We build DiabetSim to simulate different patients, events, and device conditions for scalable virtual testing and training. Using DiabetSim, we construct SweetBench by instantiating 32 scenario designs as 212 glucose-control tasks. With Claude Opus 5.5 and a fixed decision interval of one hour, APC achieves a COGI of 73.5, compared with 71.2 for the open-source closed-loop baseline OpenAPS. Ablations further show that individual adaptation and contextual information improve glucose control. Combining high-frequency rule-based control with lower-frequency agent decisions shows potential for balancing control performance and computational cost. Our work provides a framework, simulator, and evaluation foundation for agents to participate in human physiological control.

0.28

It's All in the Way You Say It: The Role of Information Representation in LLM-Based Glycemic-Event Prediction

cs.AI ·2026-09-08 ·Andrea Apicella, Pasquale Arpaia, Matteo Orefice, Andrea Pollastro, Roberto Prevete
similarity 0.38
Abstract · Submitted to a journal for peer-review

Large Language Models (LLMs) are increasingly being investigated for physiological time-series prediction, yet their effectiveness may depend not only on the model itself, but also on how physiological information is represented and presented at inference time. This study investigates prompt-based general-purpose LLMs for postprandial hyperglycemia and hypoglycemia prediction in individuals with type 1 diabetes. Using the OhioT1DM dataset, we evaluate multiple open-weight LLMs under zero-shot and few-shot inference across prediction horizons of 30, 60, and 90 minutes. The analysis varies both the textual representation of the available physiological information and the amount of information exposed to the model, ranging from glucose observations alone to derived descriptors and additional contextual variables related to insulin, meals, carbohydrates, and physical activity. Performance is compared with conventional patient-specific supervised models and with Gluco-LLM, a language-model-based architecture explicitly adapted to glucose time-series forecasting. Results show a marked task-dependent behavior. Conventional supervised models achieve the strongest performance for hyperglycemia prediction, whereas the best observed prompt-based LLM configurations improve performance for hypoglycemia across all investigated horizons. The effectiveness of prompt-based inference is also strongly influenced by how physiological information is represented, while providing additional contextual information does not lead to a systematic improvement. Overall, these findings highlight physiological information representation as a central design factor in prompt-based LLM approaches to glycemic-event prediction.

0.35

PRISMATIC : Prescription Risk Inspection System for Multi-Agent Treatment Interaction in Clinical Decision-Making

cs.CL cs.AI ·2026-10-14 ·Ziyang Ling, Shuyu Lu, Ziyi Chen
hot direction similarity 0.36
Abstract

Medical prescribing errors for multimorbid patients, who require complex drug regimens, are a major patient safety concern. These errors often stem from fragmented decision-making across medical specialties, a critical coordination failure that leads to adverse drug events and rehospitalizations. To address this coordination challenge, we introduce PRISMATIC, a multi-agent architecture where specialized agents, each representing a workflow role, collaboratively generate and refine treatment plans. Operating on a blackboard architecture, the system first structures patient information from clinical notes, then iteratively develops safe, rational, and interpretable drug regimens. The agents' collaboration is governed by two novel adaptive coordination mechanisms: (1) Dynamic Self-Updating Weight Adjustment (DSWA), a long-term mechanism that adjusts the influence weights of agents based on historical case outcomes, enabling the system to adapt and trust more reliable specialists over time. (2) Discrepancy Feedback Precise Calibration (DFPC), a short-term mechanism where agents provide iterative feedback to resolve disagreements and eliminate prescription conflicts for the current patient. Experiments on patient records from the MIMIC-IV database show that PRISMATIC significantly reduces drug conflicts, improves prescription coverage, and enhances treatment consistency compared to strong LLM baselines. Our work demonstrates that structuring clinical co-treatment as a multi-agent coordination problem offers a promising path toward safer and more coherent multidisease management.

0.29